Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
dc.contributor.author
dc.date.accessioned
2019-12-09T12:48:19Z
dc.date.available
2019-12-09T12:48:19Z
dc.date.issued
2017-09-26
dc.identifier.issn
1949-2553
dc.identifier.uri
dc.description.abstract
Triple-Negative Breast Cancer (TNBC) has poor prognosis and no approved targeted therapy. We previously showed that the enzyme fatty acid synthase (FASN) was largely expressed in a small TNBC patients’ cohort and its inhibition synergized with cetuximab in TNBC preclinical mouse models. Here, we evaluated FASN and EGFR expression in a cohort of TNBC patients and we study their prognostic role and their association with clinico-histopathological features, intrinsic TNBC subtypes and survival.
FASN, EGFR, CK5/6 and vimentin expression were retrospective evaluated by Immunohistochemistry in 100 primary TNBC tumors. FASN expression was classified into high and low FASN groups. EGFR, CK5/6 and vimentin expression were used in TNBC intrinsic subtypes classification.
FASN was expressed in most of the TNBC patients but did not correlate with overall survival or disease-free survival in this cohort. High FASN group was significantly associated with positive node status. FASN expression was significantly higher in Basal-Like patients than in Mesenchymal-Like ones. EGFR expression was positive in 50% of the tumors, and those patients showed poorer DFS. Altogether, our findings provide a rationale for further investigation the prognostic role of FASN and EGFR expression in a larger cohort of TNBC patients
dc.description.sponsorship
This work was supported in part by the Spanish Instituto de Salud Carlos III (ISCIII) (FIS PI11/00692; TP and PI14/00329; TP), Fundación Ramón Areces (TP), the Catalonian Government (2014SGR00868) and the University of Girona (MPCUdG2016/036 and predoctoral grant to AG-P)
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Impact Journals
dc.relation.isformatof
Reproducció digital del document publicat a: htps://doi.org/10.18632/oncotarget.20152
dc.relation.ispartof
Oncotarget, 2017, vol. 8, núm. 43, p. 74391-74405
dc.relation.ispartofseries
Articles publicats (D-CM)
dc.rights
Attribution 4.0 International
dc.rights.uri
dc.subject
dc.title
Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
htps://doi.org/10.18632/oncotarget.20152
dc.identifier.idgrec
027894
dc.type.peerreviewed
peer-reviewed